Novavax (NVAX) Free Cash Flow (2010 - 2026)

Novavax's Free Cash Flow history runs 17 years deep, the most recent figure standing at -$33.7 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 82.0% year-over-year to -$33.7 million; the TTM figure through Mar 2026 stood at -$91.2 million (up 50.83% YoY), while the FY2025 annual figure was -$244.6 million, down 175.35% from the prior year.
• Free Cash Flow was -$33.7 million for Q1 2026 at Novavax, up from -$39.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $320.5 million in Q2 2024 to a low of -$345.4 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$89.4 million across 5 years, with a median of -$127.3 million in 2025.
• Biggest YoY gain for Free Cash Flow was 301.93% in 2024; the steepest drop was 338.03% in 2024.
• A 5-year view of Free Cash Flow shows it stood at -$130.6 million in 2022, then plunged by 37.39% to -$179.4 million in 2023, then increased by 8.81% to -$163.6 million in 2024, then soared by 76.03% to -$39.2 million in 2025, then grew by 14.16% to -$33.7 million in 2026.
• The last three Free Cash Flow figures came in at -$33.7 million (Q1 2026), -$39.2 million (Q4 2025), and $109.0 million (Q3 2025), per Business Quant data.